ChemicalBook Product Catalog Analytical Chemistry Standard Pharmaceutical Impurity Reference Standards N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide

N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide

N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide Basic information
Product Name:N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide
Synonyms:3,3'-((3R,3'R,4R,4'R)-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis (methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxo propanenitrile);Tofacitinib-23;Tofacitinib impurity 17/Tofacitinib N-Oxide/N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide;1-Piperidinepropanenitrile, 4-methyl-3-(methyloxido-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R);1-Piperidinepropanenitrile, 4-methyl-3-(methyloxido-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3R,4R);Azilsartan medoxomil impurity334;Tofacitib related impurities 8;N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide
CAS:2028267-73-2
MF:C16H20N6O2
MW:328.37
EINECS:
Product Categories:
Mol File:2028267-73-2.mol
N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide Structure
N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide Chemical Properties
pka-1.73±0.40(Predicted)
Safety Information
MSDS Information
N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide Usage And Synthesis
N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide Preparation Products And Raw materials
N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine Tofacitinib Impurity 2 Tofacitinib Impurity 45 Tofacitinib Related Compound CYANOACETIC ACID-OSU (3S,4S)-1-Benzyl-N,4-dimethylpiperidin-3-amine 1-BENZYL-N,4-DIMETHYLPIPERIDIN-3-AMINE DIHYDROCHLORIDE (3S,4S)-1-benzyl-N,4-diMethylpiperidin-3-aMine N-(2,6-dimethylphenyl)-2-((2,6-dimethylphenyl)amino)acetamide (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride (3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine hydrochloride 3-PiperidinaMine, 1-acetyl-N,4-diMethyl-N-1H-pyrrolo[2,3-d]pyriMidin-4-yl-, (3R,4R)- (9CI) N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Tofacitinib Impurity 85 (3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine methyl3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin -4-yl)amino)piperidin-1-yl)-3-oxopropanoate 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-β-oxo- 3-Piperidinamine,4-methyl-1-(phenylmethyl)-,(3R,4R)-rel-
Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.